Supplemental material, sj-pdf-2-cep-10.1177_03331024231159366 for Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials by Faraidoon Haghdoost, Francesca Puledda, David Garcia-Azorin, Eva-Maria Huessler, Roberta Messina and Patricia Pozo-Rosich in Cephalalgia

Additional file 1. ICD‑9‑MC codes used to identify infectious process, site of infection, acute organ dysfunction and procedures used in intensive care unit.

Additional file 1: Figure S1. PRISMA flowchart of systematic review. Table S1. Pain relief at different timepoints. Table S2. Pain relief and pain-free at 2 hours. Table S3. Headache recurrence within 24 hours. Table S4. Rescue medication. Table S5. Response in triptan non-responders. Table S6. Comparisons of different triptan formulations. Table S7. Comparisons between early and late treatment with triptans. Table S8. Agreement on questions submitted in Round 1. Table S9. Conflicts of interest of...

Abstract Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder. Main body The Consensus process included a preliminary literature review, a Delphi round and...

Objectives: To explore whether time to diagnosis, time to treatment initiation and age to reach disability milestones has changed in patients with clinically isolated syndrome (CIS) according to different multiple sclerosis (MS)-diagnostic criteria periods. Methods: Retrospective study based on data prospective collected from the Barcelona-CIS cohort between 1994 and 2020. Patients were classified into five periods according to different MS criteria, and the time to MS diagnosis and treatment initiation were evaluated. The age at...

Additional file 2: Table S2. Demographic data from the fingolimod patients included in the study.

Additional file 3: Table S3. Correlations between M-MDSCs and clinical parameters after 12 months of fingolimod treatment.

Abstract Background The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the sphingosine-1-phosphate receptor modulators. In addition to inhibiting T cell egress from lymph nodes, fingolimod promotes the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs), whose monocytic subset (M-MDSCs) can be used as a...

Background:Magnetic resonance imaging (MRI) markers for chronic active lesions in MS include slowly expanding lesions (SELs) and paramagnetic rim lesions (PRLs).Objectives:To identify the relationship between SELs and PRLs in MS, and their association with disability.Methods:61 people with MS (pwMS) followed retrospectively with MRI including baseline susceptibility-weighted imaging, and longitudinal T1 and T2-weighted scans. SELs were computed using deformation field maps; PRLs were visually identified. Mixed-effects models assessed differences in Expanded Disability Status Scale (EDSS) score...

Supplemental material, sj-xlsx-3-cep-10.1177_03331024221146317 for Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization by Marta Vila-Pueyo, Ester Cuenca-León, Ana C. Queirós, Marta Kulis, Cèlia Sintas, Bru Cormand, José Ignacio Martín-Subero, Patricia Pozo-Rosich, Noèlia Fernàndez-Castillo, Alfons Macaya in Cephalalgia

Supplemental material, sj-xlsx-3-cep-10.1177_03331024221146317 for Genome-wide DNA methylation analysis in an antimigraine-treated preclinical model of cortical spreading depolarization by Marta Vila-Pueyo, Ester Cuenca-León, Ana C. Queirós, Marta Kulis, Cèlia Sintas, Bru Cormand, José Ignacio Martín-Subero, Patricia Pozo-Rosich, Noèlia Fernàndez-Castillo, Alfons Macaya in Cephalalgia

Supplemental material, sj-jpg-3-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia

Supplemental material, sj-jpg-4-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia

Supplemental material, sj-jpg-1-cep-10.1177_03331024231170807 for Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study by Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling and Patricia Pozo-Rosich in Cephalalgia

Abstract Background Influenza is an acutely debilitating respiratory infection, contributing significantly to outpatient visits and hospitalizations. Spain lacks comprehensive and updated data on the burden of influenza, particularly in the outpatient setting. Our study aimed to fill this gap by estimating the clinical and economic burden of physician-diagnosed influenza cases in adults from four Spanish regions, stratified by age groups and presence of comorbidities. Methods A retrospective cost-of-illness study was conducted using data from an...

Additional file 1: Table S1. EORTC QLQ-C30 change from baseline to C2D1. Table S2. EQ-5D-5L scores at baseline and C2D1. Figure S1. INVICTUS trial design.

Additional file 1: Table S1. Clinical data of the 21 patients included in the discovery cohort.

Additional file 3: Table S3. Discovery cohort quantitative matrix.

Additional file 5: Table S4. Parallel reaction monitoring quantitative results.

Additional file 1: Table S1. Diagnostic codes used to identify comorbidities for influenza. Table S2. Unit costs considered for each healthcare visit. (a) eSalud original reference: Consejería de Sanidad y Políticas Sociales (2020). Resolución de 6 de febrero de 2020. Diario Oficial de Extremadura, número 28, 11 de febrero de 2020 [29]. (b) Mean cost computed, using the cost for visit in regular working period of the center and outside of that period. eSalud original...

Additional file 1: Table S1. Diagnostic codes used to identify comorbidities for influenza. Table S2. Unit costs considered for each healthcare visit. (a) eSalud original reference: Consejería de Sanidad y Políticas Sociales (2020). Resolución de 6 de febrero de 2020. Diario Oficial de Extremadura, número 28, 11 de febrero de 2020 [29]. (b) Mean cost computed, using the cost for visit in regular working period of the center and outside of that period. eSalud original...

Additional file 1. Table S1. Diagnostic codes used to identify comorbidities/risk factors for influenza: a) in people ≥ 5 years old; b) in children < 5 years old. Table S2. Performance of the excess hospitalization model per age group and cause. Table S3. Performance of the excess deaths model per age group and cause. Table S4. Estimated influenza-associated excess pneumonia or influenza, respiratory, and all-cause excess hospitalizations, in absolute and per 100,000 people, by age...

Additional file 1. Table S1. Diagnostic codes used to identify comorbidities/risk factors for influenza: a) in people ≥ 5 years old; b) in children < 5 years old. Table S2. Performance of the excess hospitalization model per age group and cause. Table S3. Performance of the excess deaths model per age group and cause. Table S4. Estimated influenza-associated excess pneumonia or influenza, respiratory, and all-cause excess hospitalizations, in absolute and per 100,000 people, by age...

Additional file 1: Fig A1. Bias risk assessment.

Additional file 1: Fig A1. Bias risk assessment.